t-cell
(2)
Zhen Su
Zhen Su is the CEO of Marengo Therapeutics, a Cambridge biotech reprogramming T cells to wake up the immune system against cancer. A physician-scientist with nearly three decades in oncology, he ran a billion-dollar global cancer franchise at Merck KGaA, helped deliver eight regulatory approvals as CMO of EMD Serono, and now steers Marengo's STAR platform into the clinic on the back of a $2.8B Ipsen partnership.
Judy Chou
Dr. Judy Chou is the President, CEO, and Board Member of AltruBio Inc., a clinical-stage biotech company in San Francisco pioneering a first-in-class immune checkpoint enhancer platform targeting PSGL-1/CD162 to treat autoimmune diseases. With over 25 years of experience spanning Bayer Pharmaceuticals, Pfizer, Genentech, and Wyeth, she led AltruBio through a landmark $225M Series B financing in 2024 and is advancing lead candidate ALTB-268 through Phase 2 trials for ulcerative colitis. Recognized as one of Endpoints News' Top 20 Women in Biopharma (2025) and a Most Influential Women in Business honoree (San Francisco Business Times, 2018), she holds a Ph.D. from Yale University and conducted post-doctoral training at the Max-Planck Institute in Germany.